Abstract:We appreciate the interest in our study1 by Dr Takagi, Dr Umemoto and their team from the Department of Cardiovascular Surgery, Shizuoka Medical Centre, Shizuoka, Japan and we would like to respond. We went through the literature and reviewed many articles on the effect of preoperative statin therapy on postoperative atrial fibrillation (AF) in cardiac surgery patients.2–4 However, we found that much of the research had not really been conducted in patients who had undergone off-pump coronary artery bypass grafting (OPCABG) surgery and received preoperative statin therapy. Therefore, we took the opportunity to conduct such a trial in a domestic Chinese population, especially as AF has genetic heterogeneity and statin therapy has variable effects in different ethnic populations. However, to ensure the trial had an acceptable level of evidence, we devised it in such a way as to remove most of the biases. Consequently, we resorted to a prospective randomized, double-blind placebo-controlled trial in which the patients were randomly divided into a statin or a control group through a computer-generated randomized sequence. This study spanned a 2-year period. The medical practitioners involved in care-giving were unaware of the type of therapy (placebo or statin) the selected patients were getting. The study was conducted in a very specific and well-defined group of patients: those who were undergoing elective OPCABG and who had no history of AF prior to the surgery. Several other inclusion and exclusion criteria were established and were meticulously followed. The inclusion criteria included normal liver and kidney functions, no previous or current statin therapy, and no inflammatory disease requiring any type of anti-inflammatory treatment, which could have interfered with the already established anti-inflammatory properties of statins. Exclusion criteria included adverse reactions of statin therapy on the digestive system, altered liver function, perioperative unstable hemodynamics and/or intra-aortic balloon pump use, and postoperative important organ dysfunction. All possible factors that could have an effect on the result were included. The statin therapy was started 1 week before the elective surgery to allow time for the statin to at least start exerting its effect. The placebo was also begun at that time. In the statin group, patients were administered a daily dose of 20 mg of oral atorvastatin. The cut-off points of the study were well defined and respected. The primary endpoint was the occurrence of postoperative AF, while the secondary endpoints were major cardiac and cerebrovascular events, persistent postoperative in-hospital AF and identification of other parameters predicting postoperative AF. After the elective surgery was performed, occurrence of AF was evaluated through ECG monitoring; initially, each patient had continuous and strict ECG monitoring for at least the first 7 postoperative days and subsequently daily 12-lead ECG monitoring until hospital discharge. The occurrence and duration of postoperative AF, time of postoperative AF occurrence, and the highest ventricular rate were systematically recorded, as were postoperative complications, mortality and adverse responses to atorvastatin. At the onset of postoperative AF, patients received a single loading dose (5 mg/kg, maximum 300 mg) of intravenous amiodarone as a bolus over 30 min, followed by continuous amiodarone infusion at a rate of 0.5 mg · kg–1 · h−1. Another parameter, C-reactive protein (CRP), which is a marker of systemic inflammation, was also assessed. Measurements were carried out several times for each patient, the first before the operation and then every 24 h following surgery until discharge from hospital. Analysis of the collected data was performed using several testing options of the commercially available statistical software program SPSS 13.0. Preand perioperative independent variables were determined and their individual effects on the incidence of postoperative AF were calculated. In our study the independent risk factors for occurrence of AF after OPCABG were preoperative atorvastatin therapy, postoperative CRP level above the median value, age over 65, and proximal and middle lesions of the right coronary arteries. So, from our study we reached the conclusion that preoperative administration of a statin did significantly reduce the incidence of AF after elective OPCABG. However, our study included only moderate-risk patients. It remains to be determined if high-risk surgical patients may benefit more from preoperative administration of a statin.

Effects of Preoperative Aspirin Therapy on Early Postoperative Outcomes in Elderly Patients Undergoing Off-Pump Coronary Artery Bypass Surgery

Short-term and Long-term Postoperative Safety of Off-Pump Versus On-Pump Coronary Artery Bypass Grafting for Coronary Heart Disease: A Meta-analysis for Randomized Controlled Trials.

Effects of preoperative continued dual antiplatelet therapy on early outcomes in patients undergoing off-pump coronary artery bypass grafting

[Impact of Discontinuation of Aspirin and Clopidogrel Before Off-Pump Coronary Artery Bypass Grafting on Postoperative Bleeding and Transfusion Requirement].

Efficacy and Safety of Coronary Artery Bypass Grafting Without Stopping Pre-operative Aspirin Administration：A Meta Analysis

Effect of Preoperative Statin Therapy on Postoperative Atrial Fibrillation in Cardiac Surgery

Risk Factors for Blood Coagulation Abnormality in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting

Preoperative Treatment with Clopidogrel and Ticagrelor on Bleeding Complications in Off-Pump Coronary Artery Bypass Grafting

Effect of Preoperative Atorvastatin Therapy on Atrial Fibrillation Following Off-Pump Coronary Artery Bypass Grafting

Survival Analysis of Off-pump Coronary Artery Bypass Grafting in Patients Aged Over 75

Analysis of Risk Factors for Postoperative Atrial Fibrillation in Elderly Patients with Coronary Heart Disease after Off-Pump Coronary Artery Bypass Grafting Surgery

Effects of Aspirin Therapy on Bypass Efficacy and Survival of Patients Receiving Direct Cerebral Revascularization

Off-pump versus on-pump coronary artery bypass grafting in elderly patients at 30 days: a propensity score matching study

Effect of Preoperative Angiotensin-Converting Enzyme Inhibitor on the Outcome of Coronary Artery Bypass Graft Surgery

Early and Long-Term Outcomes in the Elderly: Comparison Between Off-Pump and On-Pump Techniques in 1191 Patients Undergoing Coronary Artery Bypass Grafting

Effect of on-pump and off-pump coronary bypass surgery on perioperative blood gases in elderly patients

Meta-analysis of Randomized Trials Comparing the Effectiveness of On-Pump and Off-Pump Coronary Artery Bypass.

Different Antithrombotic Strategies after Coronary Artery Bypass Grafting to Prevent Adverse Events: a Retrospective Analysis

Safety and Feasibility of Off-pump Coronary Artery Bypass Grafting for Elderly Patients

Is preoperative IABP insertion significantly reducing postoperative complication in augmented high-risk coronary artery bypass grafting patients?

The comparation of OPCABG and CCABG in perioperative period of high?risk coronary heart disease:a meta?analysis